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Neuroinflammation is an important contributor toAlzheimer’s disease (AD) pathogenesis, as underscored by the recent identification of
immune-related genetic risk factors for AD, including coding variants in the gene TREM2 (triggering receptor expressed on myeloid
cells 2). Understanding TREM2 function promises to provide important insights into how neuroinflammation contributes to AD pathol-
ogy. However, studies so far have produced seemingly conflicting results, with reports that amyloid pathology can be both decreased and
increased inTREM2-deficientADmousemodels. In this study,weunify theseprevious findings bydemonstrating thatTREM2deficiency
ameliorates amyloid pathology early, but exacerbates it late in disease progression in the APPPS1–21 mouse model of AD. We also
demonstrate that TREM2 deficiency decreases plaque-associated myeloid cell accumulation by reducing cell proliferation, specifically
late in pathology. In addition, TREM2 deficiency reduces myeloid cell internalization of amyloid throughout pathology, but decreases
inflammation-related gene transcript levels selectively late in disease progression. Together, these results suggest that TREM2 plays
distinct functional roles at different stages in AD pathology.
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Introduction
Alzheimer’s disease (AD) is characterized by a robust neuroin-
flammatory response (McGeer et al., 1987; Itagaki et al., 1989;
Heneka et al., 2015). In the past several years, genetic studies have
identified variants in immune-related genes that confer risk for
developing AD (Karch andGoate, 2015), directly implicating this
neuroinflammatory response in AD pathogenesis. Of these risk
factors, coding variants in the gene TREM2 (triggering receptor
expressed onmyeloid cells 2) confer the highest AD risk (Guerreiro
et al., 2013; Jonsson et al., 2013; Lill et al., 2015). TREM2 encodes
a receptor that is expressed exclusively on immune cells within
the brain (Schmid et al., 2002; Colonna, 2003) and, in AD, is
upregulated by plaque-associated myeloid cells (Frank et al.,
2008; Melchior et al., 2010; Jay et al., 2015). These brain myeloid
cells include microglia, brain-resident macrophages, and, in the
context of AD, may also include macrophages derived from pe-
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Significance Statement
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder and there are currently no effective treatments thatmodify
disease progression. However, the recent identification of genetic risk factors for AD promises to provide new insight into AD
biology and possible new therapeutic targets. Among these risk factors, variants in the gene TREM2 (triggering receptor expressed
on myeloid cells 2) confer greatly elevated risk for developing the disease. We demonstrate that TREM2 deficiency has opposing
effects onAD-relatedpathologies at early and late stagesofdiseaseprogression, unifyingpreviouswork in the field. In addition,we
examine how TREM2 affects the function of the brain immune cell populations in which it is expressed throughout disease
progression to understand possible mechanisms underlying its differential impacts on pathology.
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ripheral monocytes (El Khoury et al., 2007; Gate et al., 2010;
Koronyo et al., 2015). TREM2’s genetic linkage to AD suggests
that these myeloid cells play an important role in AD pathogen-
esis. Understandingmore about TREM2 expression and function
within these cells promises to provide insights into the complex
roles that immune cells perform in the context of AD.
To investigate the functional role of TREM2 and assess its
impact on AD pathology, recent studies examined TREM2-
deficient AD mouse models. Collectively, these studies demon-
strated that TREM2 deficiency reduces accumulation of myeloid
cells around plaques (Ulrich et al., 2014; Jay et al., 2015; Wang et
al., 2015) and attenuates inflammation-related gene expression
(Jay et al., 2015; Wang et al., 2015). However, these studies dif-
fered in their conclusions regarding the impact of TREM2 defi-
ciency on amyloid pathology (Tanzi, 2015). Jay et al. (2015)
reported reduced amyloid pathology early in disease progression
in the hippocampus of 4-month-old APPPS1;Trem2/ mice,
whereas Wang et al. (2016) found no difference in amyloid pa-
thology in the hippocampus of 4-month-old 5XFAD;Trem2/
mice compared with controls (Wang et al., 2016), but increased
amyloid accumulation at 8.5 months of age (Wang et al., 2015)
(summarized in Table 1). These opposing findings raised con-
cerns in the field about possible model-specific or facility-
dependent (Montalvo et al., 2013) effects of TREM2 deficiency
on pathology. Because these studies examined the effects of
TREM2deficiency at different time points in disease progression,
these divergent findings could also be explained by distinct roles
of TREM2 at different stages of pathology.
In this study, we assess the functional role of TREM2 in the
APPPS1 (Radde et al., 2006) AD mouse model at early and late
stages of disease to determine whether TREM2 might play a
disease-progression-dependent role in modifying AD pathology
and myeloid cell function.
Materials andMethods
Mice. The APPPS1–21 (APPPS1) mouse model of AD (provided by
Mathias Jucker) expresses human familial mutations in APP (K670M/
N671L) and PSEN1 (L166P) under the control of the Thy1 promoter
(Radde et al., 2006). These mice were crossed with Trem2/ mice
(TREM2tm1(KOMP)Vlcg) from the National Institutes of Health’s
knock-outmouse project, which express a lacZ reporter in place of exons
2, 3, and part of 4. These mice were previously characterized to lack
TREM2 expression (Jay et al., 2015). All mice were maintained on a B6
background. Because previous studies have suggested that sex may affect
the time course of pathology development in this model, both sexes of
mice were used for these experiments. The number of each sex used in
each experiment is indicated in the figure legends. Mice were housed in
the AmericanAssociation for Laboratory Animal Care-accredited facility
in the Cleveland Clinic Biological Resources Unit and all experimental
procedures were approved by the Cleveland Clinic Foundation Institu-
tional Animal Care and Use Committee.
Quantitative RT-PCR. Mice were perfused with PBS and their cortices
dissected and snap frozen on dry ice. Cortices were homogenized in PBS
with 1%NP-40, 0.5% sodium deoxycholate, and 0.1% SDS. Lysates were
added to an equal volume of RNA-Bee and kept at80°C until use. RNA
was isolated using chloroform extraction and purified using the Purelink
RNA Mini Kit (Life Technologies). Samples were treated with an on-
column DNase Purelink kit (Life Technologies). cDNA was prepared
from 500 ng of RNA using a QuantiTech Reverse Transcription kit (Qia-
gen) and qPCRperformedusing the StepOnePlus Real TimePCR system
(Life Technologies) using TaqMan assays. Relative gene expression is
graphed as the fold change gene expression. CT values were used for
statistical analyses and are reported in the results for each genotype.
Immunohistochemistry. Mice were deeply anesthetized with ketamine
xylazine and perfused with ice-cold PBS. Brains were removed and one
hemisphere was drop fixed in 4% PFA at 4°C overnight and cryopro-
tected in 30% sucrose before snap freezing in optimal cutting tempera-
ture compound. Brains were crysosectioned into 30 m sections and
stored at 4°C in PBS until use. For immunofluoresecent staining, slices
were permeabilized in PBS with 0.1% Triton X-100 and then antigen
retrieval was performed using 10 mM sodium citrate with 0.5% Tween,
pH 6.0, at 85°C for 15 min and then at room temperature (RT) for 30
min. Slices were blocked in 5% NGS/0.3% Triton X-100 in 1 PBS for
1 h and then incubated in the following primary antibodies overnight at
4°C: 6E10 (Covance, 1:1000), Iba1 (Wako, 1:1000), GFAP (Sigma-
Aldrich, 1:1000), S100 (R&D Systems, 1:500). Slices were incubated
with Alexa Fluor-conjugated secondary antibodies at a 1:1000 concen-
tration for 1 h at RT. Mouse on mouse blocking reagent (Vector Labo-
ratories) was added to the blocking solution for all antibodies raised in
mouse or rat. Slices were mounted using Prolong Gold. Cleaved caspase
3 staining (Cell Signaling Technology, 1:100)was performed as described
except antigen retrieval was performed using Reveal Decloaker (Biocare
Medical) at 85°C for 15 min and then at RT for 30 min; sections were
incubated in primary antibody for 48 h. BrdU staining (Abcam, 1:50)was
performed as described above except, after antigen retrieval, sections
were incubated in 2 MHCl at 37°C for 20min and then incubated in 0.1 M
sodium borate for 10 min at RT before blocking.
Immunohistochemistry for CD45 (ABD Serotec 1:500) followed the
same procedure with the exception of incubation in 1%H2O2 in PBS for
30min after antigen retrieval and biotinylated secondary antibodies were
used at a 1:200 concentration. Vectastain Elite ABC kit (Vector Labora-
tories) was added to sections for 1 h, followed by incubation with di-
aminobenzidine with nickel chloride. Sections were costained where
indicated with Congo Red, which has been used previously to character-
ize amyloid pathology in this AD model (Radde et al., 2006). A 1% w/v
solution of Congo Red was prepared in 80% ethanol and allowed to stir
overnight before being filtered. Sections were incubated in this Congo
Red solution for 1 h; dehydrated in 70%, 95%, and 100%ethanol; and the
tissue cleared in xylene. Slices were mounted using Permount.
Brightfield images were acquired on a Leica DMLSmicroscope using a
QImaging camera and QCapture Software (QImaging). Whole-brain
Table 1. Effects of Trem2 deficiency on AD-related pathologies










Cortex Early–middle 7 2
N/A Wang et al., 2016Hippocampus Middle 7 N/A
5XFAD;Trem2/ 8.5
Cortex Middle–late 7 2
2 Wang et al., 2015Hippocampus Late 1 2
APPPS1;Trem2/ 2 Cortex Early 2 2 7 Current Study
APPPS1;Trem2/;Cx3cr1 GFP/ 3 Unknown N/A N/A 2 N/A Wang et al., 2015
APPPS1;Trem2/ 4–4.5
Cortex Middle 7 2
2 Jay et al., 2015Hippocampus Early 2 2
APPPS1;Trem2/ 8
Cortex Late 1 2 2 Current study
Hippocampus Middle–late 7 2 (data not shown) 2 (data not shown) Current study
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images were acquired using a SCN400F slide scanner with a motorized
stage using Leica SCN Software. Confocal images were acquired on an
LSM 510 META microscope. A total of 10–30 sections 1 m apart were
stacked and reconstructed using ImageJ.
Image analysis. GFAP, S100, and CD45 expression was assessed by
determining the immunoreactive area around plaques. For these analy-
ses, one lateral and one medial section were matched for each animal.
Two representative fields, one in the motor cortex and one in the frontal
cortex, were acquired for each slice. Individual ROIs were defined by
taking a circle 100m in diameter centered in the middle of each plaque
in the field of view. These areas were then thresholded manually by a
blinded observer to distinguish immunoreactivity from background.
The percentage immunoreactive area within each ROI was recorded for
each plaque and averaged within each field of view. These values were
then averaged across images to produce the percentage immunoreactive
area/plaque value reported for each mouse.
The number of Iba1 cells per plaque was quantified. For these anal-
yses, three slices frommedial to lateral werematched and stained for each
animal. Two images were acquired per slice in randomized regions of the
cortex by an experimenter blinded to genotype. Images were taken 1m
apart from the first plane containing a plaque in the field of view through
the last. Z stacks were projected from these images and ROIs defined
around each plaque as described above. An independent blinded ob-
server quantified the number of Iba1 cell bodies within that defined
ROI. These numbers were averaged for each image and the images were
averaged together to define the number of Iba1 cells per plaque.
The number of CD45 cells per squaremillimeter was quantified. For
these analyses, slide scans of whole cortices from one medial and one
lateral matched sagittal slice were acquired. A blinded observer counted
the number of CD45 cells manually across the cortex in each section
and recorded the area of the cortex within each section. The number of
CD45 cells per square millimeter was recorded for each section and
averaged across both sections for each animal.
The number of Thioflavin S plaques per square millimeter was
quantified. For these analyses, every 12 th section across the hemibrain
was stained with ThioS and images of the whole cortex in each section
were acquired on a slide scanner. A blinded observer recorded the area of
each cortex and the number of ThioS plaques per cortex for each
section. The number of ThioS plaques per square millimeter was de-
termined for each section and these values were averaged across sections
to determine the number of ThioS plaques per square millimeter for
each animal.
6E10 immunoreactive area and plaque size were quantified from slide-
scanned images of the cortex from every 12 th section across the hemi-
brain. A blinded observer quantified these images by making ROIs
around each plaque and determining the total 6E10-immunoreactive
area for each plaque within each cortical section. The 6E10 area for
each plaque was then added together to yield the total 6E10 area for
each cortical section. This approach was used instead of making a global
threshold across the whole cortex to avoid thresholding edge effects from
tiling and nonspecific binding to blood vessels. This total 6E10 areawas
divided by the total area of the cortical section to determine the percent-
age 6E10 area for each slice. This number was averaged across all sec-
tions for each animal. Plaque size was determined from the same data
using the area recorded for each plaque in the analysis above and aver-
aging these across each section. The averages of these sections were then
recorded as average plaque area, given in arbitrary units.
The number of BrdU Iba1 cells per cortical sectionwas quantified.
For these analyses, matched lateral andmedial sections were imaged on a
slide scanner and images of Iba1 and BrdU were overlaid. A blinded
observer quantified the number of BrdU Iba1 cells in each cortical
section and these values were averaged between sections. Ki67 Iba1
cells were quantified in the same manner.
Flow cytometry. Mice were anesthetized with ketamine xylazine and
perfused with ice-cold Hank’s balanced salt solution. Brains were
chopped and digested using theMiltenyi Neural Dissociation kit at 37°C.
Cells were washed, strained, and resuspended in a 30% Percoll solution.
Then, 10% FBS was overlaid and the myelin at the interface removed
after centrifugation. Cells collected at the bottom of the gradient were
resuspended in FACS buffer (PBS, 1% BSA, 0.1% NaN3, 5 mM EDTA)
and filtered. Cells were blocked with a 1:200 concentration of CD16/
CD32 antibody (BD PharMingen) for 10 min. Samples were pooled for
unstained and single stained controls. Cells were stained with a master-
mix of CD45:AX700 (BioLegend, 1:500) and CD11b:BV605 (BioLegend,
1:500). Cells were then fixed and permeabilized using the BDBiosciences
Cytofix/Cytoperm kit and then exposed to 1 M HCl at RT for 10 min,
centrifuged, and resuspended in 0.1 M sodium borate for 5 min. Cells
were then stained in permeabilization buffer with BrdU (Abcam, 1:100)
for 30 min at RT. Cells were then washed and resuspended in permeabi-
lization buffer containing 1:1000 concentration of Alexa Fluor-488 sec-
ondary at RT for 15min. Cells were resuspended in PBS and stored at 4°C
overnight. Events were acquired on a Fortessa SORP (BD Biosciences)
and analyzed using FlowJo. For analysis, events were gated on single cells
and CD11b-positive events. Samples with5000 CD11b-positive events
were included in the analysis.
Western blotting. Tissue was extracted and processed as described
above, then sonicated and centrifuged. Protein concentration was deter-
mined using a BCA kit (Thermo Scientific). Proteins were boiled for 5
min at 95°C in sample buffer containingDTT. Then, 30g of protein per
sample was loaded into 4–12% Bis-Tris gels (Life Technologies) and run
at 100 V. Protein was transferred onto IR-compatible PVDFmembranes
on ice in a Tris glycine buffer containing methanol at 100 V for 1 h.
Membranes were blocked in a 1:1 dilution of TBS Odyssey Blocking
Buffer: TBS for 1 h at RT and incubated with the indicated primary
antibodies in blocking buffer overnight at 4°C: 6E10 (BioLegend, 1:5000)
or actin (Santa Cruz Biotechnology, 1:1000).Membranes were washed in
TBS and incubated in a 1:10,000 dilution of the appropriate IR-dye-
conjugated secondary antibody in blocking buffer for 1 h at RT. Mem-
branes were imaged and analyzed using the Odyssey imaging system.
Each sample was normalized to actin and the graphs represent these
values normalized to the mean of the APPPS1;Trem2/ group at each
time point.
Statistics. Statistical analyses were performed using GraphPad Prism. Al-
though graphed together, experiments at the 2- and 8-month time points
were performed independently, so statistical comparisons were only
made between genotypes within a given age. Two-sided, unpaired t tests
were used to determine statistical differences between groups at each
time point. Column statistics were performed to identify outliers and
these samples were excluded. Each n is a single biological replicate.
Graphs represent the mean and error bars denote the SEM. Statistical
values in the text are expressed as follows: (mean  SEM values for
APPPS1;Trem2/ vsmean SEM values for APPPS1;Trem2/, t(de-
grees of freedom)  t-value, p-value). Power analyses were not used to
determine group sizes, but the number of replicates included here are
comparable to those used in previous studies (Ulrich et al., 2015;Wang et
al., 2015; Jay et al., 2016).Mice from three separate cohorts were included
for each group.
Results
Loss of TREM2 alters the temporal progression of
amyloid pathology
To evaluate the effect of TREM2deficiency on amyloid pathology
longitudinally, we expanded on our previous work examining
4-month-old TREM2-deficient APPPS1 mice by assessing amy-
loid plaque area and number in the cortex of 2- and 8-month-old
APPPS1;Trem2/ and APPPS1;Trem2/mice. At 2months of
age, an early stage of amyloid deposition in the cortex of the
APPPS1 model, analysis of 6E10 immunoreactive area revealed a
significant reduction in total plaque area in TREM2-deficient
mice (Fig. 1e, representative images in Fig. 1a; WT 0.38 0.02 vs
KO 0.23  0.05, t(8)  2.8, p  0.021). At 4 months of age, a
midpoint in amyloid deposition in the cortex in the APPPS1
mouse model, we reported previously that there were no signifi-
cant differences in 6E10 area in the cortex (Jay et al., 2015).When
total plaque area was examined in the cortex at 8months of age, a
relatively late time point in disease progression, we found a sig-
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nificant increase in 6E10-immunoreactive area in TREM2-
deficient mice (Fig. 1e, representative images in Fig. 1b; WT
1.39 0.18 vs KO 3.04 0.38, t(11) 3.7, p 0.004). Together,
these findings demonstrate that TREM2 deficiency reduces cor-
tical plaque area early, but increases it late in disease progression
(summarized in Table 1).
We next examined the effects of TREM2 deficiency on plaque
number by quantifying the density of Thioflavin S plaques in
the cortex of 2- and 8-month old APPPS1;Trem2/ and AP-
PPS1;Trem2/ mice. At 2 months of age, there was a trend
toward a reduction in the density of Thioflavin S plaques in
TREM2-deficient mice compared with controls (Fig. 1f, repre-
sentative images in Fig. 1c; WT 0.095  0.006 vs KO 0.063 
0.014, t(12)  2.0, p  0.072), consistent with the significant re-
duction in plaque area at that time point. At 8 months of age,
we did not detect any significant differences in Thioflavin S
plaque density in TREM2-deficient APPPS1 mice (Fig. 1f, repre-
sentative images in Fig. 1d; WT 0.13  0.01 vs KO 0.13  0.02,
t(12) 0.1, p 0.930). These data suggest that TREM2 deficiency
decreases plaque number selectively at early stages of disease
progression.
To address possible explanations for the increase in total
plaque area without concomitant changes in plaque number in
TREM2-deficient mice at 8 months of age, we assessed whether
the average size of plaques in TREM2-deficient mice might be
altered late stage in disease progression.Quantification of average
plaque size revealed no significant differences between 2-month-
old APPPS1;Trem2/mice compared with APPPS1;Trem2/
mice (WT 7.07 0.98 vs KO 5.76 0.49, t(9) 1.3, p 0.240),
but, at 8months of age, therewas a striking increase in the average
plaque size inTREM2-deficientmice (Fig. 1g;WT26.79 4.57 vs
KO 60.99  9.79, t(9)  2.5, p  0.034). This is consistent with
recent findings demonstrating that TREM2deficiency can lead to
increased diffuseness of plaques with greater fibril extension
(Wang et al., 2016; Yuan et al., 2016).
We wanted to determine whether these disease progression-
dependent changes in amyloid pathology observed in the cortex
also occurred in other brain regions. We previously reported a
significant reduction in amyloid pathology in the hippocampus
of 4-month-old TREM2-deficient APPPS1 mice compared with
controls (Jay et al., 2015), an early stage in pathology in that brain
region. This led us to investigate whether amyloid plaque accu-
Figure 1. TREM2 deficiency reduces amyloid pathology early but exacerbates it late in disease progression.a,b, The 6E10-immunoreactive areawas assessed in the cortex of APPPS1;Trem2/
andAPPPS1;Trem2/mice at 2months of age (a) and 8months of age (b). c,d, Thioflavin Splaque number per squaremillimeterwas assessed in APPPS1;Trem2/ andAPPPS1;Trem2/
mice at 2 months of age (c) and 8 months of age (d). e, There was a significant reduction in 6E10 immunoreactive area in the cortex of 2-month-old TREM2-deficient mice (WT, n 3 M/2 F; KO,
n 3M/2 F) and a significant increase in 6E10 immunoreactive area in the cortex of 8-month-old TREM2-deficient mice compared with controls (WT, n 4M/2 F; KO, n 4M/3 F). f, There was
a trend toward a reduction in the density of ThioS plaque number in the cortex of 2-month-old APPPS1;Trem2/ cortex comparedwith APPPS1;Trem2/ controls (WT, n 4M/2 F; KO, n
3M/3 F), but no significant difference in ThioS plaque density in the cortex of 8-month-old TREM2-deficientmice (WT, n 4M/2 F; KO, n 5M/3 F). g, Analysis of 6E10 plaque size revealed
no significant differences in 2-month-old TREM2-deficientmice (WT,n3M/2F; KO,n3M/3F), but a significant increase in 8-month-old TREM2-deficientmice comparedwith controls (WT,n
4 M/2 F; KO, n 4 M/2 F). h, Transcript levels of human APP were assessed in 2-month-old mice (WT, n 4 M/2 F; KO, n 3 M/3 F) and 8-month-old mice (WT, n 4 M/2 F; KO, n 3 M/3 F).
i, Western blots were used to examine the protein levels of human APP using 6E10 in cortical lysates from 2-month-old mice (WT, n 3 M/2 F; KO, n 3M/2F) and 8-month-old mice (WT, n
3 M/2 F; KO, n 3 M/2 F) mice. j, APP protein levels were normalized to actin and the fold change expressed to the WT for each age. ns, Not significant; *p	 0.05; **p	 0.01.
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mulation would be affected differentially at 8 months of age, a
midpoint in disease progression in the hippocampus. We found
no significant differences in 6E10-immunoreactive area in the
hippocampus of 8-month-old APPPS1;Trem2/ mice com-
pared with controls (0.96 0.17 vs 1.52 0.29, t(11) 1.6, p
0.132). There was also a trend toward an increase in average
plaque size in the hippocampus of TREM2-deficient mice com-
paredwith controls (29.42 5.25 vs 62.71 11.43, t(9) 2.1, p
0.066; summarized in Table 1). These results indicate that there is
also a disease-progression-dependent effect of amyloid pathol-
ogy in the hippocampus of APPPS1 mice, with reductions in
amyloid pathology early, but no significant changes at amidpoint
in disease progression.
To ensure that these differences in amyloid pathology were
not due to differences in transgene expression, we assessed tran-
script (Fig. 1h) and protein levels (Fig. 1i,j) of human APP. Al-
though there was a significant reduction in APP transcript levels
in lysates from TREM2-deficient mice at 8 (WT 2.43  0.19 vs
KO 1.45  0.25, t(9)  3.1, p  0.012), but not 2 months of age
(WT 1.86 0.20 vs KO 1.89 0.15, t(10) 1.1, p 0.913), there
were no significant alterations in APP protein levels at 2 (WT
1.00 0.06 vs KO 0.89 0.11, t(8) 0.9, p 0.374) or 8months
of age (WT 1.00 0.16 vs KO 1.31 0.20, t(8) 1.2, p 0.258),
suggesting that changes in transgene expression do not drive the
changes in pathology observed in this study.
Together, these data suggest a disease progression-dependent
role for TREM2 on amyloid pathology. TREM2 deficiency ini-
tially results in reduced amyloid pathology, but leads to increased
plaque area late in disease progression. These results are consis-
tent with our previous findings, as well as those reported in
TREM2-deficient mice using other AD mouse models (summa-
rized in Table 1).
TREM2 deficiency decreases the number of CD45hi and
plaque-associated myeloid cells
Because TREM2 deficiency had opposing effects on amyloid
plaque accumulation early and late in disease progression, we
assessed whether TREM2 deficiency might affect myeloid cell
distribution and phenotype differentially at these two time
points. First, we examined gene expression of myeloid cell mark-
ers in the cortex of 2- and 8-month-old APPPS1;Trem2/ and
APPPS1;Trem2/mice to assess how TREM2 deficiency affects
different myeloid cell subsets. There were no significant changes
in expression of these myeloid cell markers in 2-month-old
TREM2-deficient mice compared with controls (Fig. 2a; PU.1
WT 11.63  0.17 vs KO 12.12  0.42, t(10)  1.1, p  0.304;
Tmem119 WT 9.80  0.17 vs KO 9.93  0.19, t(10)  0.5, p 
0.626; CD45WT14.60 0.32 vsKO14.76 0.32, t(10) 0.3, p
0.735). However, at 8 months of age, there were trends toward
reductions in the expression of the myeloid cell transcription
factor PU.1 (WT 10.42 0.28 vs KO 11.14 0.20, t(9) 2.1, p
0.060) (Scott et al., 1994) and the previously characterizedmicro-
glia specific marker Tmem119 (WT 8.64  0.09 vs KO 8.93 
0.09, t(9) 2.1, p 0.060) (Butovsky et al., 2014; Bennett et al.,
2016) in TREM2-deficient mice (Fig. 2a). In addition, the my-
eloid cell marker CD45 was reduced significantly and substan-
tially in TREM2-deficient mice at 8 months of age (Fig. 2a; WT
11.70  0.09 vs 13.60  0.24, t(9)  5.7, p  0.0003). Previous
work showed that TREM2 in APPPS1mice and other ADmodels
was expressed exclusively on myeloid cells expressing high le-
vels of CD45 throughout disease progression (Jay et al., 2015).
Because of these previous findings, and the gene expression data
in this study, we chose to distinguish myeloid cells subsets ex-
pressing high (CD45hi) and low (CD45lo) levels of this marker in
subsequent studies examining TREM2 function.
Figure 2. TREM2 deficiency reduces myeloid cell number. a, Analysis of myeloid cell markers by qPCR revealed no significant changes in expression of themyeloid cell markers PU.1, Tmem119,
or CD45 in cortical lysates from2-month-oldAPPPS1;Trem2/mice comparedwithAPPPS1;Trem2/ controls (WT,n3M/3F; KO,n3M/3F). However, therewas a trend toward reduction
in expression levels of PU.1 and Tmem119 in 8-month-old TREM2-deficient mice and a significant reduction in CD45 expression (WT, n 2 M/2 F; KO, n 3 M/4 F). b–d, Immunohistochemistry
for CD45 at 2 months of age (b; WT, n 3 M/2 F; KO, n 3 M/4 F) and 8months of age (c; WT, n 4M/2F; KO, n 4M/2F) revealed a significant decrease in the density of cells expressing high
levels of CD45 in the cortex of APPPS1;Trem2/mice compared with APPPS1;Trem2/ controls (d). ns, Not significant; **p	 0.01; ***p	 0.001.
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It was unclear whether the changes in gene expression of my-
eloid cell markers reflected a change in the total number of cells
within these myeloid cell populations or altered gene expression.
To distinguish these two possibilities, the numbers of myeloid
cells in the cortex of 2- and 8-month-old APPPS1;Trem2/ and
APPPS1;Trem2/mice were quantified. There were no signifi-
cant differences in the number of cells labeled with the pan-
myeloid cell marker Iba1 in TREM2-deficient mice compared
with controls (data not shown). However, quantification of the
number of CD45hi cells revealed a significant reduction in this
population in 2-month-old (WT 0.14 0.01 vs KO 0.02 0.005,
t(9)  16.2, p 	 0.0001) and 8-month-old APPPS1;Trem2
/
mice compared with APPPS1;Trem2/ controls (Fig. 2b–d; WT
1.26  0.11 vs 0.15  0.03, t(10)  10.2, p 	 0.0001). Together,
these data demonstrate that TREM2 deficiency affects brain my-
eloid cell number, especially at late stages in disease progression
and specifically within the CD45hi myeloid cell subset in which
TREM2 is known to be predominantly expressed.
It has been reported previously that TREM2 deficiency also
affects accumulation of myeloid cells around plaques (Jay et al.,
2015).We assessed whether TREM2 deficiency affected the accu-
mulation of myeloid cells differentially at early and late stages in
disease progression. Analysis of Iba1myeloid cell accumulation
around 6E10 plaques in 2-month-old (Fig. 3a,c; WT 3.76 
0.31 vs KO 1.75 0.21, t(9) 5.5, p 0.0004) and 8-month-old
(Fig. 3b,d; WT 9.39  0.55 vs KO 4.39  0.44, t(4)  7.1, p 
0.002) TREM2-deficient mice revealed significant reductions in
plaque-associated myeloid cells at both time points (Fig. 3e).
Consistent with our findings that CD45hi cell number was de-
creased in TREM2-deficient mice, analysis of CD45 immunore-
activity around Congo Red plaques in 2-month-old (Fig. 3f;
WT 15.40 0.74 vs KO 3.85 0.61, t(9) 12.2, p	 0.0001) and
8-month-old (Fig. 3g;WT 28.39 3.50 vs KO6.05 1.18, t(10)
6.0, p  0.0001) mice also revealed a significant reduction in
accumulation of this myeloid cell subset around plaques in
TREM2-deficient mice at both time points (Fig. 3h). Together,
these results demonstrate reduced accumulation of CD45hi my-
eloid cells associated with plaques in TREM2-deficient mice at
both early and late stages in disease progression.
TREM2 deficiency reduces myeloid cell proliferation at late
stages in disease progression
Due to the observed reduction in plaque-associatedmyeloid cells
in TREM2-deficient mice throughout the time course of pathol-
ogy, we wanted to assess whether TREM2 deficiency drove this
reduction in plaque-associated cells through different mecha-
nisms at early and late stages in disease progression. In other
disease contexts, TREM2 has been shown to play an important
role in myeloid cell proliferation (Otero et al., 2012; Cantoni et
al., 2015; Poliani et al., 2015), which could contribute to a loss of
plaque-associated myeloid cells.
We assessed whether TREM2 deficiency contributes to my-
eloid cell loss in ADmice by impairingmyeloid cell proliferation.
To examine proliferation, BrdU injections were administered
every 24 h for 72 h before mice were killed and the number of
BrdU Iba1 myeloid cells were quantified in the cortex of
APPPS1;Trem2/ and APPPS1;Trem2/ mice at 2 months
(Fig. 4a) and 8 months (Fig. 4b) of age. The numbers of prolifer-
ating cells were not altered significantly at 2 months of age (WT
16.50 2.5 vs KO 12.00 3.00, t(3) 1.2, p 0.368), but were
reduced significantly in 8-month-old TREM2-deficient mice
compared with controls (Fig. 4c;WT 74.80 3.08 vs KO 33.06
5.94, t(12) 5.0, p 0.003). An independent evaluation of pro-
liferation was performed by examining Ki67 Iba1 cell num-
bers. Similar to our BrdU analysis, we found no change in
proliferating cells per cortical section in 2-month-old APPPS1;
Trem2/ andAPPPS1;Trem2/mice (WT44.20 9.69 vs KO
37.83 8.59, t(6) 0.4, p 0.673), but a significant reduction in
TREM2-deficient mice compared with controls at 8 months of
age (WT 17.38 3.08 vs KO 6.10 0.93, t(7) 3.9, p 0.006).
Because TREM2 deficiency specifically decreased the number
of CD45himyeloid cells inAPPPS1mice, wewanted to determine
whether proliferation was affected preferentially in this myeloid
cell subset. To assess this possibility, 6- to 9-month-old APPPS1;
Trem2/mice were administered BrdU as described above and
brain myeloid cells were isolated and analyzed using flow cytom-
etry. The cells were gated on CD11b (Fig. 4d) to select the total
myeloid cell population and then divided into CD45 lo and
CD45hi populations (Fig. 4e). Quantification of the percentage of
BrdU cells within the CD45hi cell population revealed few pro-
liferating cells (0.43%; Fig. 4f). Rather, BrdU cells were primar-
ily identified within the CD45lo microglial population (7.94%;
Fig. 4g). These findings are consistent with the interpretation
that TREM2 deficiency affects CD45hi myeloid cell numbers
throughout disease progression, but has a specific impact on
CD45lo myeloid cells late in disease pathology. This reduction in
CD45lomyeloid cell proliferation is likely a contributing factor to
the loss of plaque-associated myeloid cells selectively at this late
time point and suggests that TREM2 alters myeloid cell number
early and late in disease progression through different mecha-
nisms. It remains to be determined whether this is due to target-
ing of distinctmyeloid cell subsets at different stages in pathology
or if TREM2 or myeloid cell function across myeloid cell subsets
might change throughout disease progression.
TREM2 deficiency reduces amyloid internalization,
astrocytosis, and inflammatory gene expression
Our findings indicate that TREM2 is important for the prolifer-
ation of myeloid cells late in disease progression, leading to a loss
of plaque-associated myeloid cells in TREM2-deficient mice. We
next assessed whether TREM2 deficiency and loss of these cells
would affect myeloid cell functions known to be importantmod-
ifiers of AD-related pathologies, including myeloid cell internal-
ization of amyloid, astrocytosis, and inflammation. Because
TREM2 has been shown to play an important role in phagocyto-
sis in other contexts (Takahashi et al., 2005; Hsieh et al., 2009;
Kawabori et al., 2015), we assessed whether TREM2 deficiency
affected myeloid cell internalization of amyloid plaques. Plaques
and plaque-associated myeloid cells were reconstructed from
confocal stacks and the volume of 6E10 and Iba1 colocalization
was quantified as a measure of 6E10 internalization within my-
eloid cells. This area was normalized to the total plaque volume.
At both 2 months of age (Fig. 5a; WT 14.09 2.31 vs KO 4.03
1.00, t(4)  4.0, p  0.016) and 8 months of age (Fig. 5b; WT
12.36  2.64 vs KO 2.75  0.41, t(4)  3.6, p  0.022), TREM2
deficiency resulted in significantly reduced internalization of
6E10 within myeloid cells (Fig. 5c).
Because amyloid internalization was affected both early and
late in pathology, changes in this myeloid cell function could not
explain the differential effects of TREM2 deficiency with regard
to amyloid accumulation early and late in disease progression.
Therefore, we examined whether TREM2 deficiency might affect
astrocyte activation and accumulation indirectly around plaques
differentially at these two time points. The total immunoreactive
area of the astrocyte marker GFAP around 6E10 plaques at 2
months of age (Fig. 6a; WT 5.43 1.15 vs KO 0.72 0.24, t(9)
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4.4, p 0.002) and 8 months of age (Fig. 6b; WT 26.74 2.30 vs
KO 18.60 2.30, t(10) 2.6, p 0.027) was reduced significantly
(Fig. 6c) in TREM2-deficient mice. S100 expression has been
used in other disease contexts to distinguish whether changes in
GFAP expression reflect altered astrocyte activation or are due to
a change in the distribution of astrocytes (Kang et al., 2014). To
assess whether the changes in GFAP expression observed here
were due to a reduction in plaque-proximal astrocytes, expres-
sion of the pan-astrocyte marker S100 was also examined in
2-month-old (Fig. 6d; WT 5.83 0.30 vs KO 6.43 0.29, t(9)
1.4, p 0.185) and 8-month-old (Fig. 6e;WT 10.47 0.76 vs KO
11.22 0.71, t(9) 0.7, p 0.498) TREM2-deficientmice. There
were no significant changes in S100 immunoreactive area at
either time point (Fig. 6f), suggesting that TREM2 deficiency
Figure3. TREM2deficiency reduces plaque-associatedmyeloid cells.a,b, Immunohistochemistry for Iba1 and 6E10was performed to assess accumulation ofmyeloid cells around plaques in the
cortex of 2-month-old (a) and 8-month-old (b) APPPS1;Trem2/ and APPPS1;Trem2/mice. c–e, Quantification of confocal images from 2-month-old (c) and 8-month-oldmice (d) revealed
significant reductions in the number of Iba1 cells around plaques in TREM2-deficient mice at both 2 months of age (WT, n 3 M/2 F; KO, n 3 M/3 F) and 8 months of age (WT, n 2 M/1 F;
KO, n 2 M/1 F; e). f–h, Quantification of CD45-immunoreactive area around Congo Red plaques in 2-month-old (f ) and 8-month-old (g) APPPS1;Trem2/ and APPPS1;Trem2/mice
revealed significant reductions in the CD45 hi cell accumulation around plaques in TREM2-deficientmice at both 2 (WT, n 3M/2F; KO, n 3M/3F) and 8 (WT, n 4M/2F; KO, n 4M/2F)month
time points (h). **p	 0.01; ***p	 0.001.
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likely affects the activation of astrocytes
rather than astrocyte distribution in the
brains of AD mice.
Finally, we assessed whether these
changes in myeloid cell accumulation and
astrocytosis resulted in reduced expres-
sion of inflammation-related genes. There
were no significant changes in expression
levels of several pro-inflammatory or
anti-inflammatory genes in 2-month-old
APPPS1;Trem2/ mice compared with
APPPS1;Trem2/ controls (Fig. 6g; IL1
WT14.31 0.47 vs KO 15.11 0.39, t(10)
 1.3, p 0.215; IL6 WT 15.52 0.37 vs
KO 15.35  0.50, t(10)  0.3, p  0.781;
iNOS WT 14.19  0.23 vs KO 14.29 
0.16, t(10)  0.3, p  0.751; Ym1 WT
15.20  0.70 vs KO 15.37  0.41, t(10) 
0.2, p  0.841; Fizz1 WT 14.80  0.29 vs
KO 14.95  0.68, t(10)  0.2, p  0.847;
Arg1 WT 15.26  0.66 vs KO 15.05 
0.23, t(10)  0.3, p  0.767). However,
there was a significant reduction in the in-
flammatory genes IL1 (WT 14.43 0.29
vs KO16.17 0.19, t(9) 5.2, p 0.0005)
and TNF (WT 13.07  0.30 vs KO
15.14 0.40, t(9) 3.6, p 0.006) and a
significant increase in the IL4/IL13 re-
sponse marker Fizz1 (WT 16.41 0.14 vs
KO 14.99 0.35, t(9) 2.9, p 0.016) in
TREM2-deficient mice at 8 months of age,
butno significant changes inother genes ex-
amined (IL6 WT 16.18  0.24 vs KO
16.39  0.20, t(9)  0.7, p  0.527; iNOS
WT14.87 0.09 vsKO15.31 0.22, t(9)
0.6,p0.180; Ym1WT14.420.45 vsKO
14.82  0.40, t(9)  0.6, p  0.545; Arg1
WT15.62 0.57 vsKO15.55 0.16, t(8)
0.1, p 0.894). Althoughmyeloid cell ac-
cumulation and astrocytosis were reduced at both the 2- and
8-month time points, we observed an overall reduction in
inflammation-related transcript levels selectively in 8-month-
old TREM2-deficient mice. This selective decrease in inflam-
mation could contribute to the differential impact of TREM2
deficiency on pathology at early and late stages in disease pro-
gression, but additional studies will be required to determine
the full array of changes in myeloid cell functions that contrib-
ute to these effects.
Discussion
We report that TREM2 deficiency has a disease-progression-
dependent effect on amyloid pathology and on AD-related my-
eloid cell functions. We found that loss of TREM2 results in a
reduction in plaque number and area early in disease progres-
sion, but increased plaque size and area late in pathology. TREM2
deficiency decreased accumulation of myeloid cells around
plaques and total numbers of CD45hi myeloid cells. Reduced cell
proliferation contributed to these changes, specifically at late
stages of pathology. TREM2 deficiency also reduced myeloid cell
internalization of amyloid, resulting in reduced astrocytosis at all
time points examined. We found that mice lacking TREM2 ex-
hibited selectively reduced inflammatory gene expression at late
stages of pathology.
Our findings demonstrate that TREM2 deficiency has opposing
effects on plaque burden as a function of disease progression. This
unifies the seemingly contradictory findings in the current literature.
Our previous work evaluated changes in amyloid pathology in
4-month-old APPPS1 TREM2-deficient mice and reported no
changes in the cortex, but significant reductions in the hippocam-
pus, which is at an early stage of pathology development at that time
point (Jay et al., 2015).However, others have reportedno changes in
amyloidpathology in thehippocampusofTREM2-deficient5XFAD
mice at 4 months of age, a midpoint in disease progression in the
5XFADmodel (Wang et al., 2016), and a significant increase in pa-
thology in the hippocampus of TREM2-deficient 8.5-month-old
5XFADmice (Wang et al., 2015). These opposing effects of TREM2
deficiency on amyloid pathology raised concerns about possible dif-
ferences between ADmodels or TREM2 knock-out lines. However,
our results here support that these opposing results may instead
reflect a disease-progression-dependent impact of TREM2 defi-
ciency on amyloid pathology. The possibility that TREM2 plays a
time-dependent role in disease progression has also been supported
by other work examining the effects of TREM2 overexpression in
ADmice. Jiang et al. (2014) reported alterations in amyloid pathol-
ogy inADmice inwhichTREM2wasoverexpressedat early stages in
disease progression, but more recently showed that overexpression
of TREM2 at later stages in pathology did not alter amyloid
Figure 4. TREM2 deficiency reduces myeloid cell proliferation late in disease progression. Mice were injected with 10 mg/kg
BrdU intraperitoneally every 24 h for 72 h and killed 24 h after the last injection. a, b, BrdU immunohistochemistry was used to
identify proliferating cells in 2-month-old (a) and 8-month-old (b) APPPS1;Trem2/ and APPPS1;Trem2/mice. c, Number
of BrdU Iba1 double-positive cells was quantified in the cortex of 2-month-old (WT, n 1 M/2 F; KO, n 1 M/1 F) and
8-month old (WT, n 3 M/1 F; KO, n 5 M/3 F) APPPS1;Trem2/ and APPPS1;Trem2/mice. There were no significant
differences in the numbers of proliferating myeloid cells in 2-month-old TREM2-deficient mice, but there were significant de-
creases in 8-month-oldAPPPS1;Trem2/mice comparedwithAPPPS1;Trem2/ controls.d, Brainmyeloid cellswere isolated
from 6- to 9-month-old APPPS1 mice and cells were analyzed by flow cytometry. e, Cells were gated on CD11b and divided into
CD45 lo andCD45 hi cells. f,When thepercentageofBrdU cellswasquantifiedwithin that CD45 hi population, therewere very few
proliferating cells (0.43%). g, However, there was a substantial population (7.53%) of proliferating CD45 lo cells. ***p	 0.001.
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accumulation significantly (Jiang et al., 2016). The disease-stage-
dependent role of TREM2 on AD pathology presented here recon-
ciles these previous findings and, together with other work in the
field, suggests that TREM2 deficiency reduces amyloid pathology
early, but increases it late in disease progression.
Although our findings are consistent with the known data from
human TREM2 variant carriers, as well as those using other strate-
gies to alter TREM2 expression in AD mouse models, we have not
demonstrated definitively whether this TREM2 deletion model af-
fects the expression of other gene transcripts in this locus. The
TREM2 locus also contains several immune-relatedgenes, including
some implicated in altering AD risk and pathology, such as TREM1
(Replogle et al., 2015) and TREML2 (Benitez et al., 2014), and it is
possible that expression of these or other transcripts could be af-
fected by deletion of unrecognized regulatory sequences in our
model for TREM2 deficiency. To exclude this possibility and to
more closely model changes in TREM2 function that occur in hu-
man AD, it will be important to make mouse models expressing
human TREM2 variants, including those known to promote loss of
protein functionsuchasQ33X, tovalidate findings fromtheTREM2
KOmodels reported so far and those thatmaynotconfera full lossof
function phenotype such as R47H (Kleinberger et al., 2014). These
models could provide insight into whether TREM2 deficiency fully
models the effect of human AD risk variants.
In this study, we demonstrate that TREM2 deficiency affects
some aspects of myeloid cell function in a consistent manner
throughout disease progression, including myeloid cell accumula-
tion around plaques, phagocytosis, and induction of astrocytosis.
For that reason, differential effects of TREM2 deficiency on these
myeloid cell functions cannot explain the differential effects on am-
yloid pathology at early and late time points. However, it remains
possible that alterations in myeloid cell distribution and phenotype
could have opposing impacts on amyloid accumulation at different
stages of pathology. Heneka et al. (2015) suggested thatmyeloid cell
activationcouldplaydivergent roles earlyand late indiseaseprogres-
sion,which theyproposed couldunderlie different results fromclin-
ical trials examining use of immune-targeted therapeutics such as
NSAIDs and A immunotherapy at different stages in disease pro-
gression. If this is the case, thenunderstandinghow immune-related
functions regulate pathology differentially at early and late stages of
ADwill be crucial to deciphering the biology of inflammation in the
process of neurodegeneration and designing effective inflamma-
tion-targeted therapeutics. Studying how similar effects of TREM2
deficiency early and late in disease progression result in opp-
osing pathological outcomes could provide a platform to study how
commonmyeloid cell functionsmight play different roles through-
out AD progression.
In addition to these consistent effects on myeloid cell function
throughout progression, TREM2 deficiency does exhibit stage-
specific effects on myeloid cell function. Specifically, alterations in
inflammatory gene expressionwere altered selectively late in pathol-
ogy. Several recent studies have demonstrated that reduced inflam-
mation can exacerbate amyloid pathology (Guillot-Sestier et al.;
Chakrabarty et al., 2015). Therefore, it is possible that reduced in-
flammation in TREM2-deficient mice late in disease progression
leads to the increases in amyloid accumulation observed at that time
point. In this study, we examined a small subset of the possible
inflammation-related pathways altered by TREM2 deficiency. Fu-
ture studies will be required to examine more broadly which
pathways are altered in TREM2-deficient mice and to define how
changes in these pathways contribute to amyloid pathology.
TREM2 deficiency also reduced proliferation selectively at late
stages in AD pathology. Interestingly, we found that proliferation
occurred specifically within CD45lo myeloid cells. However, we re-
ported previously that TREM2 is expressed predominantly on
CD45himacrophages in theADbrain throughout theprogressionof
pathology (Jay et al., 2015). Our previous work based on marker
expression and our unpublished findings using bone marrow chi-
meras are consistent with the identification of these cells as macro-
phages derived from peripheral monocytes. Therefore, one possible
explanation for the stage-dependent role of TREM2 deficiency on
amyloid pathology is that TREM2 deficiency affects different my-
eloid cell subsets at different stages of pathology. TREM2 deficiency
first affectsCD45himyeloid cells,where it is primarily expressed, but
later loss of theseCD45hi cells also affects the functionof theCD45lo
myeloid cells, reducing their proliferation and potentially altering
otherAD-relatedphenotypes. If these subsets are indeed reflective of
different cell origins, then these data suggest that opposing impacts
of TREM2 on resident microglia and peripherally derived macro-
phages could underlie its changing role throughout disease progres-
sion. Moving forward, it will be important to use conditional
TREM2 knock-out models to examine definitively the effects of
TREM2 deficiency in specific myeloid cell populations throughout
disease progression.
Figure 5. TREM2 deficiency reduces amyloid internalization withinmyeloid cells. a, b, Con-
focal slices through amyloid plaques were acquired 1m apart for up to 30 slices in 2-month-
old (a) and 8-month-old (b) APPPS1;Trem2/ and APPPS1;Trem2/ mice. The total
volume of colocalization between Iba1 and 6E10 was measured and normalized to plaque
volume. c, This normalized volume was reduced significantly in TREM2-deficient mice at 2
months of age (WT, n 2M/1 F; KO, n 2M/1 F) and 8months of age (WT, n 1M/2 F; KO,
n 3M). *p	 0.05.
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Wepropose thatTREM2deficiency first results in loss ofCD45hi
myeloid cells from the AD brain. These cells may normally play an
important role in altering the local brainmicroenvironment in AD,
inducing a local inflammatory response in cells surrounding amy-
loid plaques. Loss of these CD45hi myeloid cells results in reduced
activation of plaque-associated astrocytes and, later in disease pro-
gression, decreased activation and proliferation of CD45lo micro-
glia. The reduction in CD45hi myeloid cells mediated by TREM2
deficiency initially results in decreased amyloid pathology through
mechanisms that are not yet understood. However, later in disease
progression, when CD45lo myeloid cell function is also affected, re-
duced amyloid internalization and decreased inflammatory gene
transcription likely contribute to increasedplaque size andanoverall
increase in amyloid accumulation.
Since the identification of TREM2 variants as risk factors for
AD, there has been substantial interest in TREM2 as a potential
inflammation-related therapeutic target. Recognizing the dual role
for TREM2 function early and late in disease progression provides
important insights into theunderlyingbiologyofTREM2 inADand
suggestsnewconsiderations in thedevelopmentofTREM2-directed
therapeutics. This study suggests that trials using TREM2-directed
therapies will have to consider carefully the disease stage being tar-
geted. The time point in progression at which these therapeutics are
deliveredcouldcritically affect clinicaloutcomes.These findings also
suggest that disease progression might be an important factor to
consider in the use of inflammation- or immune-cell-targeted ther-
apeutics in general in the context of AD.
References
Benitez BA et al. (2014) Missense variant in TREML2 protects against Alz-
heimer’s disease. Neurobiol Aging 35:1510e19–26. CrossRef Medline
Bennett ML, Bennett FC, Liddelow SA, Ajami B, Zamanian JL, Fernhoff NB,
Figure6. TREM2deficiency reduces astrocytosis and inflammation.a,b, Immunohistochemistry for GFAP and6E10was performed to assess astrocytosis in 2-month-old (a) and 8-month-old (b)
APPPS1;Trem2/ and APPPS1;Trem2/mice. c, Quantification of the GFAP-immunoreactive area around plaques revealed significant reductions in TREM2-deficient mice at 2 months of age
(WT, n 3M/2 F; KO, n 3M/3 F) and 8months of age (WT, n 4M/2 F; KO, n 4M/3 F). d–f, S100-immunoreactive area around 6E10 plaqueswas also examined at 2months of age (d)
and 8months of age (e) and revealed no significant differences between genotypes at either time point (f; 2 MWT, n 3M/ 2F; 2 M KO, n 3M/3 F; 8 MWT, n 4M/2 F; 8 M KO, n 3M/2 F).
g, Expression of inflammation-related transcripts was quantified using qPCR. There were no significant changes in expression of these genes in TREM2-deficient mice at 2 months of age (WT, n
3 M/3 F; KO, n 3 M/3 F). However, there was a significant reduction in the pro-inflammatory genes IL1 and TNF and a significant increase in the anti-inflammatory marker Fizz1 in
TREM2-deficient mice at 8 months of age (WT, n 2 M/2 F; KO, n 3 M/4 F). *p	 0.05; **p	 0.01; ***p	 0.001.
646 • J. Neurosci., January 18, 2017 • 37(3):637–647 Jay et al. • Role of TREM2 Throughout AD Progression
Mulinyawe SB, Bohlen CJ, Adil A, Tucker A, Weissman IL, Chang EF, Li
G, Grant GA, Hayden Gephart MG, Barres BA (2016) New tools for
studying microglia in the mouse and human CNS. Proc Natl Acad Sci
U S A 113:E1738–E1746. CrossRef Medline
Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G,
Koeglsperger T, Dake B, Wu PM, Doykan CE, Fanek Z, Liu L, Chen Z,
Rothstein JD, Ransohoff RM, Gygi SP, Antel JP, Weiner HL (2014)
Identification of a unique TGF- dependent molecular and functional
signature in microglia. Nat Neurosci 17:131–143. CrossRef Medline
Cantoni C, Bollman B, Licastro D, Xie M, Mikesell R, Schmidt R, Yuede CM,
Galimberti D, Olivecrona G, Klein RS, Cross AH, Otero K, Piccio L
(2015) TREM2 regulates microglial cell activation in response to demy-
elination in vivo. Acta Neuropathol 129:429–447. CrossRef Medline
Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, FunkCC,Moore B, DiNunno
N, Rosario AM, Cruz PE, Verbeeck C, Sacino A, Nix S, Janus C, Price ND,
Das P, Golde TE (2015) IL-10 alters immunoproteostasis in APP mice,
increasing plaque burden and worsening cognitive behavior. Neuron 85:
519–533. CrossRef Medline
Colonna M (2003) TREMs in the immune system and beyond. Nat Rev
Immunol 3:445–453. CrossRef Medline
ElKhoury J,ToftM,HickmanSE,MeansTK,TeradaK,GeulaC,LusterAD (2007)
Ccr2 deficiency impairs microglial accumulation and accelerates progression of
Alzheimer-like disease.NatMed13:432–438.CrossRefMedline
Frank S, Burbach GJ, Bonin M, Walter M, Streit W, Bechmann I, Deller T
(2008) TREM2 is upregulated in amyloid plaque-associated microglia in
aged APP23 transgenic mice. Glia 56:1438–1447. CrossRef Medline
Gate D, Rezai-Zadeh K, Jodry D, Rentsendorj A, Town T (2010) Macro-
phages in Alzheimer’s disease: the blood-borne identity. J Neural Transm
117:961–970. CrossRef Medline
Guerreiro R et al. (2013) TREM2 variants in Alzheimer’s disease. N Engl
J Med 368:117–127. CrossRef Medline
Guillot-Sestier MV, Doty KR, Gate D, Rodriguez J Jr, Leung BP, Rezai-Zadeh
K, Town T (2015) Deficiency rebalances innate immunity to mitigate
Alzheimer-like pathology. Neuron 85:534–548. CrossRef Medline
HenekaMT et al. (2015) Neuroinflammation inAlzheimer’s disease. Lancet
Neurol 14:388–405. CrossRef Medline
Hsieh CL, KoikeM, Spusta SC, Niemi EC, Yenari M, NakamuraMC, SeamanWE
(2009) Arole forTREM2ligands in thephagocytosisof apoptoticneuronal cells
bymicroglia. JNeurochem109:1144–1156.CrossRefMedline
Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D (1989) Relationship of
microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neu-
roimmunol 24:173–182. CrossRef Medline
Jay TR et al. (2015) TREM2 deficiency eliminates TREM2 inflammatory
macrophages and ameliorates pathology in Alzheimer’s disease mouse
models. J Exp Med 212:287–295. CrossRef Medline
Jiang T,Wan Y, Zhang YD, Zhou JS, GaoQ, Zhu XC, Shi JQ, LuH, Tan L, Yu
JT (2016) TREM2 overexpression has no improvement on neuropa-
thology and cognitive impairment in aging APPswe/PS1dE9 mice. Mol
Neurobiol. In press. CrossRef Medline
Jonsson T et al. (2013) Variant of TREM2 associated with the risk of Alzhei-
mer’s disease. N Engl J Med 368:107–116. CrossRef Medline
Kang W, Balordi F, Su N, Chen L, Fishell G, He´bert JM (2014) Astrocyte
activation is suppressed in both normal and injured brain by FGF signal-
ing. Proc Natl Acad Sci U S A 111:E2987–E2995. CrossRef Medline
Karch CM, Goate AM (2015) Alzheimer’s disease risk genes and mechanisms of
disease pathogenesis. Biol Psychiatry 77:43–51.CrossRefMedline
Kawabori M, Kacimi R, Kauppinen T, Calosing C, Kim JY, Hsieh CL, Naka-
mura MC, Yenari MA (2015) Triggering Receptor Expressed on My-
eloid Cells 2 (TREM2) Deficiency Attenuates Phagocytic Activities of
Microglia and Exacerbates Ischemic Damage in Experimental Stroke.
J Neurosci 35:3384–3396. CrossRef Medline
Kleinberger G et al. (2014) TREM2 mutations implicated in neurodegen-
eration impair cell surface transport and phagocytosis. Sci Transl Med
6:243ra286. CrossRef Medline
Koronyo Y, Salumbides BC, Sheyn J, Pelissier L, Li S, Ljubimov V, Moyseyev
M, Daley D, Fuchs DT, Pham M, Black KL, Rentsendorj A, Koronyo-
HamaouiM (2015) Therapeutic effects of glatiramer acetate and grafted
CD115() monocytes in a mouse model of Alzheimer’s disease. Brain
138:2399–2422. CrossRef Medline
Lill CM et al. (2015) The role of TREM2 R47H as a risk factor for Alzhei-
mer’s disease, frontotemporal lobar degeneration, amyotrophic lateral
sclerosis, and Parkinson’s disease. Alzheimers Dement 11:1407–1416.
CrossRef Medline
McGeer PL, Itagaki S, Tago H, McGeer EG (1987) Reactive microglia in
patients with senile dementia of the Alzheimer type are positive for the
histocompatibility glycoprotein HLA-DR. Neurosci Lett 79:195–200.
CrossRef Medline
Melchior B, Garcia AE,Hsiung BK, LoKM,Doose JM, Thrash JC, Stalder AK,
Staufenbiel M, Neumann H, Carson MJ (2010) Dual induction of
TREM2 and tolerance-related transcript, Tmem176b, in amyloid trans-
genic mice: implications for vaccine-based therapies for Alzheimer’s dis-
ease. ASN Neuro 2:e00037. CrossRef Medline
Montalvo V, Quigley L, Vistica BP, Boelte KC, Nugent LF, Takai T, McVicar
DW, Gery I (2013) Environmental factors determine DAP12 deficiency
to either enhance or suppress immunopathogenic processes. Immunol-
ogy 140:475–482. CrossRef Medline
Otero K, ShinoharaM, ZhaoH, CellaM, Gilfillan S, Colucci A, Faccio R, Ross
FP, Teitelbaum SL, Takayanagi H, ColonnaM (2012) TREM2 and beta-
catenin regulate bone homeostasis by controlling the rate of osteoclasto-
genesis. J Immunol 188:2612–2621. CrossRef Medline
Poliani PL,WangY, FontanaE, RobinetteML, Yamanishi Y,Gilfillan S, ColonnaM
(2015) TREM2 sustainsmicroglial expansion during aging and response to de-
myelination. JClin Invest 125:2161–2170.CrossRefMedline
Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L,
CalhounME, Ja¨ggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C,
Ho¨lscher C, Mathews PM, Jucker M (2006) Abeta42-driven cerebral
amyloidosis in transgenicmice reveals early and robust pathology. EMBO
Rep 7:940–946. CrossRef Medline
Replogle RA, Chan G, White CC, Raj T, Winn PA, Evans DA, Sperling RA,
Chibnik LB, Bradshaw EM, Schneider JA, Bennett DA, De Jager PL
(2015) A TREM1 variant alters the accumulation of Alzheimer-related
amyloid pathology. Ann Neurol 77:469–477. CrossRef Medline
Schmid CD, Sautkulis LN, Danielson PE, Cooper J, Hasel KW, Hilbush BS,
Sutcliffe JG, CarsonMJ (2002) Heterogeneous expression of the trigger-
ing receptor expressed on myeloid cells-2 on adult murine microglia.
J Neurochem 83:1309–1320. CrossRef Medline
Scott E, Simon MC, Anastasi J, Singh H (1994) Requirement of transcrip-
tion factor PU.1 in the development of multiple hematopoietic lineages.
Science 265:1573–1577. CrossRef Medline
Takahashi K, Rochford CD, Neumann H (2005) Clearance of apoptotic
neurons without inflammation by microglial triggering receptor ex-
pressed on myeloid cells-2. J Exp Med 201:647–657. CrossRef Medline
Tanzi RE (2015) TREM2 and Risk of Alzheimer’s Disease— Friend or Foe?
N Engl J Med 372:2564–2565. CrossRef Medline
Ulrich JD, FinnMB,Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio
L, ColonnaM, Holtzman DM (2014) Altered microglial response to A
plaques in APPPS1–21 mice heterozygous for TREM2. Mol Neurode-
gener 9:20–20. CrossRef Medline
Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S,
KrishnanGM,SudhakarS,ZinselmeyerBH,HoltzmanDM,CirritoJR,Colonna
M (2015) TREM2 lipid sensing sustains the microglial response in an Alzhei-
mer’s diseasemodel. Cell 160:1061–1071.CrossRefMedline
Wang Y, Ulland TK, Ulrich JD, SongW, Tzaferis JA, Hole JT, Yuan P,Mahan
TE, Shi Y, Gilfillan S, Cella M, Grutzendler J, DeMattos RB, Cirrito JR,
Holtzman DM, Colonna M (2016) TREM2-mediated early microglial
response limits diffusion and toxicity of amyloid plaques. J Exp Med
213:667–675. CrossRef Medline
Yuan P, Condello C, Keene CD,Wang Y, Bird TD, Paul SM, LuoW, Colonna
M,BaddeleyD,Grutzendler J (2016) TREM2haploinsufficiency inmice
and humans impairs the microglia barrier function leading to decreased
amyloid compaction and severe axonal dystrophy. Neuron 90:724–739.
CrossRef Medline
Jay et al. • Role of TREM2 Throughout AD Progression J. Neurosci., January 18, 2017 • 37(3):637–647 • 647
